Publicly Traded Hemp-Focused Wellness Company Reports Q2 Results, Here Is What You Need To Know
Portfolio Pulse from Nina Zdinjak
CV Sciences, Inc. (OTCQB:CVSI) reported Q2 2023 financial results, with revenue of $4.0 million, compared to $4.1 million for the same period of 2022. The company's gross profit was $1.72 million, compared to $1.27 million in Q2 2022. The gross margin was 43.3%, versus 30.7% in Q2 2022. The net loss was $1.29 million, compared to a net loss of $2.65 million in Q2 2022. The company's shares were trading 2.07% higher at $0.0385 per share.
August 14, 2023 | 2:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CV Sciences reported improved gross profit and margin, and reduced net loss in Q2 2023. The company's shares were trading higher following the announcement.
CV Sciences reported improved financial performance in Q2 2023, with higher gross profit and margin, and a reduced net loss compared to the same period in 2022. This positive financial performance is likely to have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100